$9,543.33 consulting Payment -- Takeda Pharmaceuticals to Dr. Daniel White

Payment Details

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Takeda Pharmaceuticals made a $9.5K consulting payment to Daniel White, a Gastroenterology specialist in City, CO. The payment was associated with Stelara. The payment of $9,543.33 to Dr. Daniel White for consulting services is related to Takeda Pharmaceuticals. The payment was made on October 3, 2025, and is associated with the drug Stelara. Dr. White's specialty is Gastroenterology, and the payment was for consulting fees.

Patient Guidance: What This Payment Means for You

This information details a payment made to your doctor for consulting services related to a specific medication. It's important to discuss all treatment options and potential conflicts of interest with your healthcare provider. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Consulting fees for specialists like gastroenterologists can vary widely, but this amount for a single consulting engagement may be considered moderate compared to some other reported payments.

Regulatory Context: Sunshine Act Requirements

Payments from pharmaceutical companies to physicians are subject to disclosure under the Sunshine Act (part of the Affordable Care Act) to promote transparency in healthcare.

Related Topics

This payment is related to the following healthcare transparency topics:

• pharmaceutical-payments
• physician-compensation
• consulting-fees
• gastroenterology
• drug-marketing
• open-payments-data

Understanding consulting Payments

Consulting payments are made when pharmaceutical companies hire physicians as advisors or consultants. This can include serving on advisory boards, providing expert medical opinions on drug development or marketing strategies, and reviewing clinical data. Consulting is one of the most common forms of pharmaceutical payment to physicians and can range from a few hundred dollars for a brief consultation to tens of thousands of dollars for ongoing advisory relationships.

Frequently Asked Questions About This Payment

What was this $9.5K payment for?

This was a consulting payment of $9.5K from Takeda Pharmaceuticals to Daniel White, categorized as "Consulting Fee". It was associated with Stelara. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Daniel White accept pharmaceutical money?

Yes, Daniel White received this $9.5K payment from Takeda Pharmaceuticals. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Daniel White's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this consulting payment?

A consulting payment of $9.5K may reflect legitimate advisory services the physician provides. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Gastroenterology?

To compare this payment against Gastroenterology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Gastroenterology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Daniel White's relationship with Takeda Pharmaceuticals?

The payment amount is a specific consulting fee, not a general payment. This $9.5K consulting payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Gastroenterology?

The payment is linked to a specific drug, Stelara, indicating potential influence on prescribing habits.

What should patients do after learning about this payment?

This information details a payment made to your doctor for consulting services related to a specific medication. It's important to discuss all treatment options and potential conflicts of interest with your healthcare provider.

What else should I know about this consulting payment?

The date of payment is in the future (2025), which is unusual for historical CMS data.

Related Reports

• View Dr. Daniel White's full payment report
• Takeda Pharmaceuticals full spending report
• Browse all Gastroenterology payments
• Browse all payments in Colorado
• Search for other payments